These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20610831)

  • 41. Differential effects of fingolimod on B-cell populations in multiple sclerosis.
    Nakamura M; Matsuoka T; Chihara N; Miyake S; Sato W; Araki M; Okamoto T; Lin Y; Ogawa M; Murata M; Aranami T; Yamamura T
    Mult Scler; 2014 Sep; 20(10):1371-80. PubMed ID: 24526661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
    Hohlfeld R
    Nat Rev Neurol; 2011 Jul; 7(8):425-7. PubMed ID: 21750524
    [No Abstract]   [Full Text] [Related]  

  • 43. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
    Weissert R
    Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
    [No Abstract]   [Full Text] [Related]  

  • 44. Avoiding infusion therapy prime benefit of new MS drug.
    Morrow T
    Manag Care; 2010 Aug; 19(8):49-50. PubMed ID: 20822073
    [No Abstract]   [Full Text] [Related]  

  • 45. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
    Filippi M
    Nat Rev Neurol; 2011 Feb; 7(2):74-5. PubMed ID: 21297650
    [No Abstract]   [Full Text] [Related]  

  • 46. Fingolimod modulates peripheral effector and regulatory T cells in MS patients.
    Serpero LD; Filaci G; Parodi A; Battaglia F; Kalli F; Brogi D; Mancardi GL; Uccelli A; Fenoglio D
    J Neuroimmune Pharmacol; 2013 Dec; 8(5):1106-13. PubMed ID: 23649711
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fingolimod. Mitsubishi Pharma/Novartis.
    Dumont FJ
    IDrugs; 2005 Mar; 8(3):236-53. PubMed ID: 15772896
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O; Küry P; Kieseier B; Hartung HP
    Nat Rev Neurol; 2010 Jul; 6(7):373-82. PubMed ID: 20551946
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
    Komoly S
    Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
    [No Abstract]   [Full Text] [Related]  

  • 50. Fingolimod for multiple sclerosis: a review for the specialist nurse.
    Harrison K
    Br J Nurs; 2014 Jun 12-25; 23(11):582-9. PubMed ID: 24933548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging disease-modifying oral therapies for multiple sclerosis.
    Losy J; Kalinowska-Łyszczarz A
    J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
    Johnson TA; Lapierre Y; Bar-Or A; Antel JP
    Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Emerging treatments for multiple sclerosis].
    Nau JY
    Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
    [No Abstract]   [Full Text] [Related]  

  • 54. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
    García-Merino JA; Sánchez AJ
    Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reconstitution of circulating lymphocyte counts in FTY720-treated MS patients.
    Johnson TA; Shames I; Keezer M; Lapierre Y; Haegert DG; Bar-Or A; Antel J
    Clin Immunol; 2010 Oct; 137(1):15-20. PubMed ID: 20599429
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D; Gilden D
    Neurology; 2012 Nov; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract]   [Full Text] [Related]  

  • 57. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The experience of using fingolimod (gilenya) in patients with relapsing-remitting multiple sclerosis].
    Kotov SV; Fedorova SI; Iakushina TI; Lizhdvoĭ VIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):74-8. PubMed ID: 23528598
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
    Aktas O; Ingwersen J; Kieseier B; Küry P; Hohlfeld R; Hartung HP
    Nervenarzt; 2011 Feb; 82(2):215-25. PubMed ID: 20842337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A sphingosine-1 phosphate agonist (FTY720) limits trauma/hemorrhagic shock-induced multiple organ dysfunction syndrome.
    Bonitz JA; Son JY; Chandler B; Tomaio JN; Qin Y; Prescott LM; Feketeova E; Deitch EA
    Shock; 2014 Nov; 42(5):448-55. PubMed ID: 25004059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.